Praesidian doubles up with pharma deal
The mezzanine firm’s second investment in Meta Pharmaceutical Services brings its exposure to $14m.
10 July 2013•1 min read
The mezzanine firm’s second investment in Meta Pharmaceutical Services brings its exposure to $14m.
